Efficacy and Safety of Semaglutide According to Frailty Status
Researchers analyzed secondary data from the SELECT randomized clinical trial to evaluate whether frailty status modifies the efficacy and safety of semaglutide in adults with cardiovascular disease and overweight/obesity. Participants were categorized by a frailty index into not frail, more frail, and most frail groups. The study compared semaglutide with placebo. Results indicated that semaglutide benefits on the primary cardiovascular outcome were consistent across frailty categories, and the improvement in health-related quality of life was greater in those with higher frailty.
What to check after reading
Frailty status did not significantly alter the primary cardiovascular benefit of semaglutide, though higher frailty was associated with greater quality of life improvement.
Source
Calendar dates show when a case was added or scheduled. For event dates, check the original source.